ARCT - Arcturus Therapeutics Holdings Inc.
| Previous Close | 11.54 |
| Open | 11.54 |
| Bid | 9.80 x 1400 |
| Ask | 16.00 x 900 |
| Day's Range | 11.41 - 12.43 |
| 52 Week Range | 4.26 - 15.50 |
| Volume | 52,932 |
| Avg. Volume | 73,777 |
| Market Cap | 187.257M |
| Beta (5Y Monthly) | 2.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.33 |
| Earnings Date | Nov 06, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.50 |
- Simply Wall St.
The Arcturus Therapeutics Holdings (NASDAQ:ARCT) Share Price Has Gained 114%, So Why Not Pay It Some Attention?
When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right...
- GlobeNewswire
Arcturus Therapeutics Appoints Steve Hughes, M.D., as Chief Development Officer
SAN DIEGO, Jan. 08, 2020 -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Arcturus Therapeutics Ltd. (ARCT)
The market has been volatile in the last few months as the Federal Reserve finalized its rate cuts and uncertainty looms over trade negotiations with China. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by more than 10 percentage […]
- ACCESSWIRE
Arcturus Therapeutics to Present at the Investor Summit on December 17th in Philadelphia.
PHILADELPHIA, PA / ACCESSWIRE / December 11, 2019 / Arcturus Therapeutics (ARCT), will be presenting at this year's Investor Summit on December 17th in Philadelphia. The Investor Summit will take place ...
- Simply Wall St.
Rock star Growth Puts Arcturus Therapeutics Holdings (NASDAQ:ARCT) In A Position To Use Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
- GlobeNewswire
Arcturus Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 07, 2019 -- Arcturus Therapeutics Holdings Inc. (“Arcturus Therapeutics”) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery,.
- GlobeNewswire
Arcturus Therapeutics Expands Platform with STARR Technology™
SAN DIEGO, Nov. 07, 2019 -- Arcturus Therapeutics (NASDAQ: ARCT, the “Company”), a leading messenger RNA medicines company focused on the discovery, development and.
- GlobeNewswire
Arcturus Therapeutics to Report Corporate Overview and Financial Results on November 7th
SAN DIEGO, Nov. 04, 2019 -- Arcturus Therapeutics (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of.
- Zacks
Will Arcturus Therapeutics (ARCT) Report Negative Q3 Earnings? What You Should Know
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Arcturus Therapeutics (ARCT) Upgraded to Buy: Here's What You Should Know
Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- GlobeNewswire
Arcturus Therapeutics to Present at Three Upcoming Investor Conferences
SAN DIEGO, Oct. 02, 2019 -- Arcturus Therapeutics Holdings Inc. (“Arcturus Therapeutics”) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery,.
- Zacks
Ultragenyx Gets FDA Approval for Label Expansion of Crysvita
Ultragenyx (RARE) and partner Kyowa Kirin get FDA approval for the label expansion of Crysvita in pediatric patients with X-linked hypophosphatemia.
- GlobeNewswire
Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock
Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company focused on the discovery, development and commercialization of mRNA therapeutics for rare diseases, today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale in a registered direct offering of 850,000 shares of the Company’s common stock, at a purchase price of $11.50 per share, for aggregate gross proceeds of approximately $9.8 million. The Company intends to use the net proceeds from this offering to fund its continued research and development initiatives in connection with its product pipeline including, but not limited to LUNAR-CF, LUNAR-CV, LUNAR-MD and general corporate purposes.
- GlobeNewswire
Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. and Re-Appointment of Andy Sassine to the Board of Directors
SAN DIEGO, Sept. 23, 2019 -- Arcturus Therapeutics Holdings Inc. (“Arcturus Therapeutics”) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery,.
- Simply Wall St.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Insiders Increased Their Holdings
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
- Zacks
Ultragenyx-GeneTx Get Orphan Drug Status for GTX-102 From FDA
The FDA grants Orphan Drug and Rare Pediatric Disease designations to Ultragenyx (RARE) and partner GeneTx Biotherapeutics' GTX-102 for the treatment of Angelman Syndrome.
- GuruFocus.com
Arcturus Therapeutics Holdings Inc (ARCT) President and CEO Joseph E Payne Bought $56,100 of Shares
President and CEO of Arcturus Therapeutics Holdings Inc (30-Year Financial, Insider Trades) Joseph E Payne (insider trades) bought 5,000 shares of ARCT on 08/29/2019 at an average price of $11.22 a share. Continue reading...
- GuruFocus.com
Arcturus Therapeutics Holdings Inc (ARCT) CFO Andy Sassine Bought $109,000 of Shares
CFO of Arcturus Therapeutics Holdings Inc (30-Year Financial, Insider Trades) Andy Sassine (insider trades) bought 10,000 shares of ARCT on 08/23/2019 at an average price of $10.9 a share. Continue reading...
- GlobeNewswire
Arcturus Therapeutics To Present at Two Investor Conferences in September
SAN DIEGO, Aug. 26, 2019 -- Arcturus Therapeutics Holdings Inc. (“Arcturus Therapeutics”) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery,.
- Zacks
Ultragenyx (RARE) Focuses on Pipeline Amid Low Revenues
Ultragenyx (RARE) focuses on the development of pipeline candidates. Being a new commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses.
- Zacks
What Makes Arcturus Therapeutics (ARCT) a New Strong Buy Stock
Arcturus Therapeutics (ARCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- Zacks
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 86.79% and 153.26%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Arcturus Therapeutics Announces Second Quarter Financial Results and Provides a Corporate Update
Ultragenyx Pharmaceutical, Inc. expands collaboration, becoming Arcturus’ largest shareholderCystic Fibrosis Foundation increases commitment to $15 millionArcturus receives.
- Zacks
Can European Expansion Aid Canopy Growth (CGC) Q1 Earnings?
Canopy Growth's (CGC) recent acquisition of European companies will help it expand its production footprint into one of the most promising international regions.
- Zacks
Can Cannabis Therapy Drive Canopy Growth's (CGC) Q1 Earnings?
Canopy Growth (CGC) expects to deliver a strong first-quarter fiscal 2020 on solid performance by its cannabis therapy business.
